Video Series

Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) severely affects patients’ quality of life and daily functioning, with a median survival that underscores the disease’s severity, while also highlighting the substantial financial burden and health care resource utilization associated with managing this condition.

Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) is a specific form of interstitial lung disease characterized by progressive lung scarring, which leads to significant respiratory impairment and distinct clinical challenges compared with other interstitial lung diseases.

Panelists discuss how health care providers can improve patient education and support for type 2 inflammatory conditions through personalized communication strategies and shared decision-making, while also evaluating the role of emerging biologic therapies in treatment plans based on individual patient factors, disease severity, and biomarker profiles.

Panelists discuss how incorporating HER2-directed therapies into NSCLC management strategies within managed care settings impacts clinical outcomes, operational processes, and economic considerations, while emphasizing the importance of identifying and selecting patient populations most likely to benefit from these targeted treatments.

A panel of experts explores the objectives and design of the COORDINATE-Diabetes trial, discussing its potential impact on the treatment paradigm for diabetes management.

Panelists discuss how persistent unmet needs in HER2-directed therapy for NSCLC present opportunities for future research and pipeline therapies, potentially addressing challenges such as treatment resistance, improved efficacy, or reduced toxicity profiles.

A panel of cardiometabolic risk management experts analyzes key takeaways from the UH CINEMA Program.

Panelists discuss the considerations guiding treatment choices for lupus nephritis, such as drug interactions, patient characteristics, and steroid use, and how treatment approaches might differ between nephrologists and rheumatologists.

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.

Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer.

Medical experts explore the psychological and emotional aspects of decision-making for patients in the third-line stage of metastatic colorectal cancer, recommend involving support services like social work or palliative care, and discuss the caregiver’s role in supporting patients through these psychosocial challenges.

Panelists discuss how type 2 inflammatory diseases can lead to potential long-term complications or comorbidities, including airway remodeling in asthma, nasal polyps in chronic rhinosinusitis, skin thickening in atopic dermatitis, and increased risk of cardiovascular issues and metabolic disorders.

Medical experts examine strategies for care coordination in high-risk patients with cardiometabolic conditions.

Panelists discuss how recent clinical trial results for emerging HER2-directed therapies, including findings from the SOHO-01 study, inetetamab/pyrotinib combination study, and Beamion LUNG-1, are shaping the future landscape of NSCLC treatment, while also highlighting other noteworthy developments presented at this year’s World Conference on Lung Cancer.

Key opinion leaders explore educational initiatives aimed at enhancing guideline adherence in cardiometabolic risk management, emphasizing effective tactics for improving health outcomes.

Panelists discuss how clinicians carefully weigh the efficacy of HER2-directed therapies against their safety profiles, particularly focusing on managing serious adverse events like interstitial lung disease, while also considering emerging strategies to combat resistance to these treatments as research in the field progresses.

Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for increasing early diagnosis and screening in patients with systemic lupus erythematosus.

Panelists discuss the updated treatment recommendations for lupus nephritis in the Kidney Disease Improving Global Outcomes and European Alliance of Associations for Rheumatology guidelines, how they differ from previous guidelines, and the influence of these clinical guidelines on the evaluation of treatment options.

Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.

Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.

Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that specifically address the underlying inflammatory mechanisms rather than relying solely on symptomatic treatments.

Panelists discuss how the selection between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine is guided by findings from pivotal trials like DESTINY-Lung01 and DESTINY-Lung02, real-world patient outcomes compared with clinical trial results, and the management of common treatment-related adverse events associated with these HER2-directed therapies.

Panelists discuss how HER2-directed therapies in non–small cell lung cancer (NSCLC) are evolving, with experts examining the distinction between HER2 mutation and expression, evaluating the efficacy and safety of current treatments like trastuzumab deruxtecan and ado-trastuzumab emtansine, and considering their potential to reshape treatment approaches as recommended in NCCN guidelines.

Key opinion leaders explore educational initiatives aimed at enhancing guideline adherence in cardiometabolic risk management, emphasizing effective tactics for improving health outcomes.

The expert panel analyzes strategies for overcoming barriers to prescribing first-line medications for cardiometabolic conditions.

Panelists discuss the main cost drivers of lupus nephritis treatment, comparing direct medical costs to those of other chronic conditions and examining indirect costs such as lost productivity and disability.

Panelists discuss the significant clinical and economic burdens of lupus nephritis, including the increased risk of kidney failure and death, and provide current statistics on the prevalence and incidence of lupus nephritis in various populations.

Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment selection, balancing efficacy, safety, and overall prognosis.

Panelists discuss how biomarkers of type 2 inflammation, such as blood eosinophils, serum IgE, and fractional exhaled nitric oxide, can aid in diagnosing and monitoring type 2 inflammatory diseases as well as in predicting treatment response.

Experts in cardiometabolic risk management examine the factors contributing to low adherence to guidelines for cardiometabolic conditions, with a specific focus on type 2 diabetes.